Saturday, February 9, 2019, Charlotte, North Carolina, 8:00 AM – 4:00 PM

Year in Review — A Multitumor Regional Symposia Series Focused on the Application of Emerging Research Information to the Care of Patients with Common Cancers


Saturday, February 9, 2019

Program Time:
8:00 AM – 4:00 PM
Breakfast and lunch buffet to be provided

The Ballantyne Hotel and Lodge
10000 Ballantyne Commons Parkway
Charlotte, NC 28277
Hotel Phone: (704) 248-4000

Meeting Room:
Ballantyne Ballroom (Lobby Level)

There is no registration fee for this event. Preregistration is advised as seating is limited.

Acute Leukemias

Harry P Erba, MD, PhD
Instructor, Department of Medicine
Duke Cancer Institute
Duke University School of Medicine
Durham, North Carolina

Mark J Levis, MD, PhD
Professor of Oncology, Medicine and Pharmacology
Division of Hematologic Malignancies
Johns Hopkins University School of Medicine
Co-Director, Hematologic Malignancies and Bone Marrow Transplantation Program
Director, Adult Leukemia Service
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

Breast Cancer

Matthew P Goetz, MD
Professor of Oncology and Pharmacology
Mayo Clinic
Rochester, Minnesota

Additional faculty to be announced

Gastrointestinal Cancers

Tanios Bekaii-Saab, MD
Mayo Clinic College of Medicine and Science
Co-Leader, GI Cancer Program
Mayo Clinic Cancer Center
Senior Associate Consultant
Mayo Clinic, Arizona
Scottsdale, Arizona

Eileen M O’Reilly, MD
Associate Director, Clinical Research
David M Rubenstein Center for Pancreas Cancer
Attending Physician, Member
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Medical College of Cornell University
New York, New York

Philip A Philip, MD, PhD
Professor of Oncology and Pharmacology
Director of GI and Neuroendocrine Tumors
Vice President of Medical Affairs
Karmanos Cancer Institute
Wayne State University
Detroit, Michigan

Genitourinary Cancers

David I Quinn, MBBS, PhD
Medical Director, Norris Cancer Hospital and Clinics
Head, GU Cancer Section
Division of Cancer Medicine and Blood Diseases
USC/Norris Comprehensive Cancer Center
Los Angeles, California

Additional faculty to be announced

Lung Cancer

D Ross Camidge, MD, PhD
Professor of Medicine/Oncology
Joyce Zeff Chair in Lung Cancer Research
University of Colorado Cancer Center
Aurora, Colorado

Additional faculty to be announced

Lymphoma and Chronic Lymphocytic Leukemia

Christopher Flowers, MD, MS
Professor of Hematology and Medical Oncology
Emory School of Medicine Winship Cancer Institute
Atlanta, Georgia

Ann S LaCasce, MD, MMSc
Program Director, Fellowship in Hematology/Oncology
Associate Professor of Medicine
Harvard Medical School
Lymphoma Program
Dana-Farber Cancer Institute
Boston, Massachusetts

John P Leonard, MD
Richard T Silver Distinguished Professor
of Hematology and Medical Oncology
Associate Dean for Clinical Research
Weill Cornell Medical College
New York, New York

Ovarian Cancer

Ursula A Matulonis, MD
Medical Director and Program Leader
Gynecologic Oncology Program
Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Additional faculty to be announced

Neil Love, MD
Research To Practice
Miami, Florida


Each module will include a moderated slide presentation reviewing key publications, presentations and ongoing trials in addition to a clinical decision-making track facilitated through the use of networked tablet technology. The event will take place from 8:00 AM to 4:00 PM (breakfast and lunch buffets to be provided).

MODULE 1: Gastrointestinal (GI) Cancers

  • Clinical decision-making for patients with newly diagnosed metastatic colorectal cancer (CRC): Importance of biomarker profile, primary tumor sidedness, prior therapy and other factors
  • Rational incorporation of anti-EGFR therapy, regorafenib and TAS-102 into current treatment algorithms; patient selection, side-effect management and optimal dosing/sequencing
  • FDA approval of and patient selection for nivolumab in combination with ipilimumab for mismatch repair-deficient/microsatellite instability-high CRC
  • Identification of and treatment for patients with other potentially targetable genetic abnormalities (eg, BRAF, HER2)
  • Integration of ramucirumab into clinical algorithms for metastatic HER2-negative and HER2-positive gastric/gastroesophageal junction (GEJ) cancer
  • Available trial data with anti-PD-1/PD-L1 antibodies in patients with advanced gastric/GEJ cancer; optimal integration of pembrolizumab into current clinical algorithms
  • Design, entry criteria and key efficacy and safety data from the Phase III TAGS study of TAS-102 for previously treated metastatic gastric cancer
  • Available Phase III data comparing lenvatinib to sorafenib for advanced hepatocellular carcinoma (HCC); recent FDA approval of lenvatinib for first-line therapy
  • Sequence and selection of approved options for patients with progressive HCC who have previously received sorafenib
  • Available research data and ongoing evaluation of anti-PD-1/PD-L1 antibodies for HCC
  • Major efficacy and tolerability findings from the CELESTIAL trial; potential clinical role of cabozantinib in the management of HCC
  • Key efficacy outcomes from the REACH-2 study; improvement in overall and progression-free survival with ramucirumab for patients with progressive HCC and elevated alpha-fetoprotein levels
  • Efficacy and safety results from the Phase III PRODIGE 24/CCTG PA.6 trial comparing adjuvant mFOLFIRINOX to gemcitabine for patients with resected pancreatic cancer
  • Current nonresearch role, if any, of FOLFIRINOX or nanoparticle albumin-bound (nab) paclitaxel/gemcitabine in the neoadjuvant and adjuvant settings
  • Selection and sequencing of therapy for patients with metastatic pancreatic cancer; optimal integration of nanoliposomal irinotecan into clinical practice
  • Incidence of BRCA1/2 mutations in patients with pancreatic cancer; available data and ongoing evaluation of PARP inhibitors for metastatic pancreatic cancer
  • Ongoing investigation of other novel agents and strategies in metastatic pancreatic cancer (eg, PEGPH20, napabucasin, ibrutinib)
  • Current clinical algorithms for the management of GI neuroendocrine tumors (NET)
  • Optimal employment of long-acting somatostatin analogues for patients with GI NET
  • Recent FDA approval and current clinical role of lutetium 177Lu Dotatate for gastroenteropancreatic carcinoid NET

MODULE 2: Acute Leukemias

  • Assessment, incidence and prognostic or predictive relevance of cytogenetic and other molecular biomarkers (eg, FLT3 mutations, IDH1/2 mutations)
  • Available data with and current clinical role of CPX-351 for newly diagnosed, therapy-related acute myeloid leukemia (AML) or AML with myelodysplasia-related changes
  • Current management approaches for FLT3-mutated AML
  • Mechanisms of action, available research and emerging Phase III data with gilteritinib and quizartinib for FLT3 mutation-positive AML
  • Research database supporting FDA approvals of the IDH inhibitors enasidenib and ivosidenib for relapsed/refractory (R/R) AML; optimal integration into current algorithms
  • Current clinical role of gemtuzumab ozogamicin for CD33-positive AML
  • Available data and ongoing evaluation of venetoclax in the management of AML
  • Selection and sequencing of therapy for patients with Philadelphia chromosome-positive and negative acute lymphoblastic leukemia (ALL)
  • FDA-endorsed use of blinatumomab for patients with minimal residual disease (MRD)-positive ALL in first or second complete remission or those with R/R disease
  • Research data supporting the FDA endorsement of inotuzumab ozogamicin for R/R B-cell precursor ALL
  • Optimal integration of tisagenlecleucel into the treatment of progressive ALL in pediatric and young adult patients; ongoing clinical investigation of anti-CD19 chimeric antigen receptor (CAR) T-cell platforms in adult populations
  • Current management of acute promyelocytic leukemia

MODULE 3: Lymphoma and Chronic Lymphocytic Leukemia (CLL)

  • MRD assessment in CLL: Available platforms, clinical significance and current protocol and nonresearch applications
  • Selection and sequencing of therapy for patients with newly diagnosed and relapsed CLL
  • Practical integration of venetoclax into current clinical algorithms for relapsed disease
  • Available data and current and potential role of acalabrutinib in the management of CLL
  • Biologic rationale for, early activity with and ongoing evaluation of novel combination approaches for untreated or R/R CLL (eg, ibrutinib/FCR, ibrutinib/venetoclax, ibrutinib/obinutuzumab)
  • Clinical and research implications of the Phase III RELEVANCE trial results evaluating the “R-squared” regimen of lenalidomide/rituximab in newly diagnosed follicular lymphoma (FL)
  • Emerging data from the Phase III AUGMENT trial of R-squared in R/R FL
  • Current clinical role of obinutuzumab-based induction and maintenance therapy for previously untreated FL
  • Mechanism of action, available efficacy and safety data and FDA approval of copanlisib for R/R FL
  • Clinical implications of the recent FDA approval of brentuximab vedotin (BV) with doxorubicin/vinblastine/dacarbazine (AVD) as first-line therapy for advanced classical Hodgkin lymphoma (HL)
  • Anti-PD-1/PD-L1 antibodies for newly diagnosed or R/R HL: Long-term outcomes and ongoing investigation in combination with other agents (eg, BV, anti-CTLA-4 antibodies)
  • Available data and ongoing evaluation of novel agents (eg, bortezomib, lenalidomide, ibrutinib, acalabrutinib) as a component of induction therapy for untreated mantle cell lymphoma (MCL)
  • Mechanism of action, tolerability and FDA-endorsed indication for the second-generation Bruton tyrosine kinase inhibitor acalabrutinib in R/R MCL
  • Early data and potential nonresearch role of venetoclax — alone or in combination with ibrutinib — for treatment-refractory MCL
  • Available data with approved and investigational anti-CD19 CAR T-cell platforms for patients with large B-cell lymphomas
  • Patient identification and appropriate referral for consideration of axicabtagene ciloleucel and tisagenlecleucel therapy
  • Biologic rationale for, early results with and ongoing investigation of other novel agents and immunotherapeutic strategies for diffuse large B-cell lymphomas (eg, lenalidomide, polatuzumab vedotin, anti-PD-1/PD-L1 antibodies)

MODULE 4: Genitourinary Cancers

  • Phase III research data, FDA approvals and current clinical roles of apalutamide and enzalutamide for nonmetastatic castration-resistant prostate cancer (CRPC)
  • Mechanism of action, available research data and ongoing Phase III investigation of the novel antiandrogen darolutamide
  • Current management of hormone-sensitive metastatic prostate cancer
  • Clinical and biologic factors guiding the selection and sequencing of secondary hormonal therapy, immunotherapy and cytotoxic therapy for metastatic CRPC (mCRPC)
  • Published research documenting the correlation between the presence of AR-V7 (androgen receptor splice variant 7) and outcomes with secondary hormonal therapy or chemotherapy for patients with mCRPC
  • Current indications for radium-223 dichloride in clinical practice and rational combination strategies
  • Incidence of somatic or germline mutations (eg, BRCA1, BRCA2 or ATM) in patients with mCRPC; ongoing evaluation of PARP inhibition as a therapeutic strategy
  • Selection and sequencing of therapy for patients with metastatic renal cell carcinoma (mRCC)
  • Available data with anti-PD-1 monotherapy as front-line treatment for mRCC; implications for future trial design and clinical practice
  • Key clinical findings from the IMmotion151 study of atezolizumab/bevacizumab versus sunitinib for untreated mRCC
  • FDA breakthrough therapy designations and ongoing evaluation of avelumab/axitinib and pembrolizumab/lenvatinib for mRCC
  • Research database supporting the FDA approvals of atezolizumab, avelumab, durvalumab, nivolumab and pembrolizumab for urothelial bladder cancer (UBC); patient selection and use of these agents in clinical practice
  • Rationale for and clinical implications of recent revision of FDA approvals of atezolizumab and pembrolizumab limiting their use for patients with metastatic UBC who have not received prior therapy
  • FDA breakthrough therapy designation for enfortumab vedotin for patients with locally advanced or metastatic UBC who previously received immune checkpoint inhibitor therapy; ongoing trials and development timeline

MODULE 5: Lung Cancer

  • Optimal integration of osimertinib into current treatment algorithms; effect of EGFR variant, if any, on the selection of first-line therapy
  • Available clinical trial data guiding the selection of first and subsequent lines of therapy for patients with newly diagnosed ALK-positive non-small cell lung cancer (NSCLC)
  • Current and emerging treatment options for patients with ROS1 translocations or BRAF V600E tumor mutations
  • Protocol and nonresearch options for patients with other oncogenic drivers (eg, HER2, MET exon 14, RET, NTRK gene fusions)
  • Correlation between PD-L1 tumor proportion score and responsiveness to anti-PD-1/PD-L1 therapy; implications of the Phase III KEYNOTE-042 trial results
  • Results from the Phase III KEYNOTE-189 trial; patient selection for and current role of carboplatin/pemetrexed/pembrolizumab as first-line therapy for nonsquamous NSCLC
  • Key efficacy and safety findings from the Phase III IMpower150 study evaluating atezolizumab/bevacizumab in combination with carboplatin/paclitaxel for previously untreated advanced nonsquamous NSCLC
  • Emerging role of anti-PD-1/PD-L1 antibodies in combination with chemotherapy as first-line treatment for advanced squamous NSCLC; results from the Phase III KEYNOTE-407 and IMpower131 trials
  • Biologic rationale for the evaluation of anti-PD-1/PD-L1 antibodies in combination with anti-CTLA-4 antibodies; results from the Phase III CheckMate 227 trial evaluating nivolumab/ipilimumab for lung cancer with a high tumor mutational burden
  • Major efficacy and safety findings from the PACIFIC trial; role of sequential durvalumab in the management of unresectable Stage III NSCLC
  • Ongoing evaluation of other anti-PD-1/PD-L1 antibodies in the localized and locally advanced settings
  • Biologic rationale for and available data with immune checkpoint inhibition in small cell lung cancer (SCLC); NCCN endorsement of nivolumab/ipilimumab for patients with progressive metastatic SCLC
  • Design, eligibility criteria and key efficacy outcomes from the Phase III IMpower133 trial of carboplatin/etoposide with or without atezolizumab for patients with untreated extensive-stage SCLC

MODULE 6: Ovarian Cancer (OC)

  • Identification of “BRCA-like” and other genomic signatures (eg, HRD) that may predict benefit from PARP inhibition
  • Effect of BRCA mutation status on the activity of PARP inhibitors in OC; proposed mechanisms of anticancer activity in patients without an identified BRCA mutation
  • Current clinical role of bevacizumab as a component of up-front and/or maintenance therapy for newly diagnosed OC
  • Emerging data from the Phase III SOLO-1 trial evaluating maintenance therapy with olaparib for patients with BRCA-mutated OC after first-line platinum-based chemotherapy
  • FDA indications and patient selection for niraparib, olaparib or rucaparib for platinum-sensitive recurrent OC; patient- and disease-specific factors that influence the prioritization of one agent versus another
  • Available data documenting the correlation between low baseline body weight or platelet counts and adverse events with niraparib; implications for initial dosing
  • Design, recently presented results and clinical implications of the Phase II QUADRA study of niraparib for patients with relapsed OC, regardless of mutation status, who have received 3 or more prior chemotherapy regimens
  • Early efficacy and tolerability data with PARP inhibitors in combination with chemotherapy and/or anti-angiogenic agents; late-stage clinical trials
  • Biologic rationale and eligibility criteria for ongoing trials of PARP inhibitors combined with immune checkpoint inhibitors
  • Mechanism of action, safety and efficacy findings and ongoing trials of mirvetuximab soravtansine for OC
  • Available data and ongoing evaluation of anti-PD-1/PD-L1 antibodies alone or in combination with other therapies for OC
  • Other targeted agents under investigation in OC

MODULE 7: Breast Cancer (BC)

  • TAILORx intermediate-risk cohort results and implications for the use of the 21-gene signature assay to facilitate decision-making regarding adjuvant systemic therapy
  • Available research data guiding the use of approved CDK4/6 inhibitors for pre-, peri- and postmenopausal patients diagnosed with ER-positive metastatic BC (mBC)
  • Recently published data sets supporting the ongoing investigation of other novel agents and strategies for patients with ER-positive disease
  • FDA approval and patient selection for pertuzumab as a component of adjuvant therapy for early HER2-positive BC
  • Optimal integration of postadjuvant neratinib into current clinical algorithms; prophylaxis and expectant management of associated side effects
  • Optimal management of HER2-positive metastatic disease; novel HER2-directed therapies
  • Indications for BRCA analysis in BC and optimal testing platforms
  • Phase III data sets documenting the efficacy of PARP inhibitors in patients with germline BRCA-mutated, HER2-negative mBC; integration of olaparib into current algorithms
  • Available data and ongoing evaluation of anti-PD-1/PD-L1 antibodies as monotherapy or in combination with other therapeutic agents
  • Emerging results from the Phase III IMpassion130 trial evaluating atezolizumab in combination with nab paclitaxel as first-line therapy for metastatic triple-negative BC

Target Audience:
This live activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows, nurse practitioners, clinical nurse specialists and other allied cancer professionals.

Learning Objectives and Goals:
At the conclusion of this activity, participants should be able to:

  • Effectively apply the results of practice-changing clinical research to the care of patients with breast, lung, gastrointestinal, genitourinary, ovarian and select hematologic cancers.
  • Appraise the clinical relevance of recent pivotal cancer research results published in peer-reviewed journals and/or presented at major oncology conferences.
  • Recall ongoing trials in breast, lung, gastrointestinal, genitourinary, ovarian and select hematologic cancers, and refer appropriate patients for study participation.
  • Use an understanding of tumor biomarkers and single and multigene signatures to individualize the care of patients with cancer.
  • Educate patients with diverse hematologic cancers and solid tumors about the benefits and risks of new therapeutic agents and strategies.
  • Refine or validate existing cancer-specific treatment algorithms based on exposure to new data sets and the perspectives of tumor-specific clinical investigators.
  • Evaluate the mechanisms of action, tolerability and efficacy of promising investigational agents, and consider their potential implications for clinical practice.

Accreditation Statements:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Research To Practice is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

CME Credit Designation Statement:
Research To Practice designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE Credit Designation Statements:
This educational activity for 6.6 contact hours is provided by Research To Practice.

This activity is awarded 6.6 ANCC pharmacotherapeutic contact hours.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information:
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit

ONCC review is only for designating content to be used for recertification points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the CNE provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.

CME Credit Form:
A credit form will be given to each participant at the conclusion of the activity.

CNE Credit Form:
To obtain a certificate of completion and receive credit for this event, nurses must sign in at the registration desk upon arrival, attend the entire activity and return a completed Educational Assessment and Credit Form upon exiting the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC):
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME/CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Unlabeled/Unapproved Uses Notice:
There is no implied or real endorsement of any product by RTP, ACCME or the ANCC. Any off-label use as declared by the FDA will be identified.

Educational Support:
This activity is supported by educational grants from AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Amgen Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boston Biomedical Pharma Inc, Celgene Corporation, Clovis Oncology, Eisai Inc, Exelixis Inc, Genentech, Genomic Health Inc, Guardant Health, ImmunoGen Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Lilly, Loxo Oncology, Merck, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Seattle Genetics, Taiho Oncology Inc and Tesaro Inc.

Research To Practice CME/CNE Planning Committee Members, Staff and Reviewers:
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

The Ballantyne Hotel and Lodge
10000 Ballantyne Commons Parkway
Charlotte, NC 28277
Hotel Phone: (704) 248-4000

Meeting Room: Ballantyne Ballroom (Lobby Level)

North Carolina Oncology Association (NCOA) and South Carolina Oncology Society (SCOC) members, please be sure to contact the Ballantyne Hotel directly to book accommodations in the NCOA/SCOS room block.

This live activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows, nurse practitioners, clinical nurse specialists and other allied cancer professionals.

At this time registration for this educational activity is limited to practicing clinicians. For all other professionals,* we are unable to confirm seating at this time. If you would like to stand by for participation in this event, please provide your contact information by choosing the second registration option below. Should seats become available for the program, we will notify you.

There is no registration fee for this event. Preregistration is advised as seating is limited.

Registration for clinicians in practice

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

Registration for clinicians in practice »
Standby registration for other/industry professionals*

If you would like to stand by for participation in this event, please provide your contact information here.

Registration for other/industry professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at or (800) 233-6153.
To ensure seating, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Meal service will be provided to those who attend the program, based on availability.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational programs.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.